TFR Capital LLC. Invests $1.59 Million in Cencora, Inc. (NYSE:COR)

TFR Capital LLC. acquired a new stake in shares of Cencora, Inc. (NYSE:COR - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 5,718 shares of the company's stock, valued at approximately $1,590,000.

Other large investors have also made changes to their positions in the company. Cornerstone Planning Group LLC increased its stake in Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock valued at $26,000 after acquiring an additional 48 shares during the period. Hoey Investments Inc. bought a new stake in Cencora in the first quarter valued at about $28,000. Banque Transatlantique SA bought a new stake in Cencora in the fourth quarter valued at about $29,000. Vermillion Wealth Management Inc. bought a new stake in Cencora in the fourth quarter valued at about $38,000. Finally, Golden State Wealth Management LLC increased its stake in Cencora by 157.6% in the first quarter. Golden State Wealth Management LLC now owns 170 shares of the company's stock valued at $47,000 after acquiring an additional 104 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total value of $4,266,106.98. Following the completion of the transaction, the chairman owned 311,913 shares of the company's stock, valued at approximately $91,271,982.06. This trade represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the transaction, the chief executive officer directly owned 47,582 shares of the company's stock, valued at approximately $13,766,900.06. This trade represents a 9.46% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 34,127 shares of company stock valued at $9,812,296 in the last three months. 10.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

COR has been the topic of a number of analyst reports. Citigroup upped their target price on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Robert W. Baird upped their price objective on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. UBS Group upped their price objective on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the stock an "equal weight" rating in a research note on Wednesday. Finally, Bank of America upped their target price on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and a consensus target price of $309.83.

Cencora Trading Up 1.1%

NYSE COR traded up $3.18 during trading hours on Wednesday, hitting $297.83. The company's stock had a trading volume of 1,323,704 shares, compared to its average volume of 1,505,493. The stock has a fifty day moving average of $291.96 and a 200 day moving average of $271.13. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. The firm has a market capitalization of $57.73 billion, a P/E ratio of 34.55, a PEG ratio of 1.46 and a beta of 0.57. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. The company had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the business posted $3.80 earnings per share. Equities research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.74%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio is 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.